AbbVie stock rose $8.20 to $265.05 as of 11:16 a.m. EDT, extending a multi-month rally that has lifted the shares more than 30% over the past three months. The pharmaceutical company is scheduled to report second-quarter 2026 financial results before the market opens on July 31, followed by a conference call. In the first quarter, AbbVie delivered worldwide net revenues of $15.0 billion, up 12% on a reported basis and 10% on a constant-currency basis. The company raised its full-year adjusted EPS guidance at that time. Skyrizi and Rinvoq have remained central to the growth story as AbbVie works through the ongoing erosion of Humira sales following the loss of exclusivity.